0 12

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy

Authors
 Jang Ho Cho  ;  Jae Yun Lim  ;  Jae Yong Cho 
Citation
 PLoS One, Vol.12(10) : e0186362, 2017 
Journal Title
 PLoS One 
Issue Date
2017
MeSH
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage* ; Capecitabine/administration & dosage ; Chemotherapy, Adjuvant/adverse effects ; Chemotherapy, Adjuvant/methods* ; Disease-Free Survival ; Drug Combinations ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology* ; Female ; Gastrectomy ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Oxonic Acid/administration & dosage ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Tegafur/administration & dosage ; Treatment Outcome
Abstract
AIM: To compare capecitabine and oxaliplatin (XELOX) with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. METHODS: Clinical data from 206 patients who received XELOX or S-1 regimens as adjuvant chemotherapy in stage III gastric cancer were collected. Patients were divided into 2 groups according to regimen; the groups were XELOX (n = 114) and S-1 monotherapy (n = 92). RESULTS: 3-year disease-free survival (DFS) was higher in the S-1 group than in the XELOX group (66.6% vs 59.1%; p = 0.636). 3-year overall survival (OS) was 75.6% in the S-1 group and 69.6% in the XELOX group (p = 0.495). But, the difference was not statistically significant. Especially, for patients with stage IIIC disease, 3-year overall survival was 55.2% in the XELOX group and 39.0% in the S-1 group (hazard ratio, HR 0.50, 95% confidence interval, CI 0.23-1.10; p = 0.075). In multivariate analysis, N stage (HR, 5.639; 95% CI, 1.297-24.522; p = 0.021) and cycle completion as planned (HR, 5.734; 95% CI, 3.007-10.936; p<0.001) were independent predictors of overall survival. CONCLUSION: Adjuvant XELOX and S-1 regimen did not prove anything superior for stage III gastric cancer in this study. But, XELOX had a tendency to be superior to S-1 in stage IIIC gastric cancer after D2 gastrectomy although the difference was not statistically significant. N stage and cycle completion as planned were prognostic factors.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165784
DOI
10.1371/journal.pone.0186362
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
조재용(Cho, Jae Yong) ORCID logo https://orcid.org/0000-0002-0926-1819
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse